Bioluminescence in drug development for cancer: Shedding light on therapeutic efficacy

Abstract

Commentary to:

Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267

Jessica Kalra, Malathi Anantha, Corinna Warburton, Dawn Waterhouse, Hong Yang, Young-joo Yang, Dita Strut, Maryam Osooly, Dana Masin and Marcel B. Bally

This article refers to:

Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267